Mesoblast (MEOBF) Liabilities and Shareholders Equity (2014 - 2026)

Mesoblast has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $773.1 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 1.48% year-over-year to $773.1 million; the TTM figure through Jun 2026 stood at $3.0 billion (up 7.78% YoY), while the FY2026 annual figure was $773.1 million, down 1.48% from the prior year.
• Liabilities and Shareholders Equity came in at $773.1 million for Q2 2026 at Mesoblast, down from $782.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $784.7 million in Q2 2025 to a low of $650.4 million in Q1 2023.
• Average Liabilities and Shareholders Equity over 5 years is $695.8 million, with a median of $669.8 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity declined 11.09% in 2022 and gained 19.74% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $668.1 million in 2022, then increased by 0.33% to $670.3 million in 2023, then slipped by 2.53% to $653.3 million in 2024, then climbed by 19.74% to $782.3 million in 2025, then decreased by 1.18% to $773.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $773.1 million in Q2 2026, $782.3 million in Q4 2025, and $784.7 million in Q2 2025.